Leah S. Millheiser, M.D.
A safety and efficacy trial of flibanserin in premenopausal women with HSDD
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
The purpose of this study is to find out if the investigational drug, flibanserin, is safe and effective for the treatment of women with HSDD.
Recruiting Status:
No longer recruitingStanford Recruiting Status:
No longer recruitingCondition(s):
Intervention(s):
- Drug: flibanserin
Phase:
Phase 3Eligibility
Ages Eligible for Study:
18 years to Any AgeGenders Eligible for Study:
FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
1. Women age 18 or older at time of screening.
2. Premenopausal women with a primary diagnosis of HSDD.
Key Exclusion Criteria:
Additional Study Details
Official Title:
A twenty-four week, randomized, double-blind, placebo-controlled, safety and efficacy trial of flibanserin 25 milligrams twice daily and 50 milligrams once and twice daily in premenopausal women with hypoactive sexual desire disorder in North AmericaAnticipated start date:
11/1/2006Lead Sponsor:
Boehringer Ingelheim Pharmaceuticals, Inc.Investigator(s):
Study Type:
InterventionalPurpose:
TreatmentAllocation:
RandomizedMasking:
Double BlindControl:
noneAssignment:
ParallelEndpoints:
Safety/EfficacyPrimary Outcomes:
- Increase in sexual desire
Total Number to be Enrolled:
1400Total Number to be Enrolled at Stanford:
18More Information
Secondary ID(s):
- 6282
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
10/19/2007PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help